title: [Novel target therapies used in breast cancer management].
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Semiglazova
authors.forename: V V
authors.initials: VV
authors.lastname: Semiglazov
authors.forename: L V
authors.initials: LV
authors.lastname: Filatova
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: V A
authors.initials: VA
authors.lastname: Chudenko
authors.forename: D Kh
authors.initials: DKh
authors.lastname: Latipova
authors.forename: V S
authors.initials: VS
authors.lastname: Luk'ianchikova
authors.forename: G A
authors.initials: GA
authors.lastname: Dashian
authors.forename: R M
authors.initials: RM
authors.lastname: Paltuev
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D000077341:Lapatinib; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D011960:Receptors, Estrogen / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077341:Lapatinib; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D011804:Quinolines; D053245:RANK Ligand; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D000068878:Trastuzumab; C505688:TNFSF11 protein, human; C508053:ERBB2 protein, human; C487932:neratinib; C485206:pertuzumab